Save the Date: TR 10th Anniversary

Hard to believe, but the 10^th Anniversary of Timmerman Report is coming up in March 2025.

Time to party!

The past 10 years of biotechnology have been remarkable. I’m fortunate. I’ve had a front-row seat to chronicle monumental advances at Timmerman Report, and occasionally influence events.

Join me and a group of biotech leaders in Boston on Mar. 6 and in Seattle on Mar. 13 for the TR10 Anniversary Celebrations. 

TR10 East Coast Celebration

Mar. 6, Alnylam Pharmaceuticals, 675 West Kendall St. Cambridge, Mass.

5 pm. Registration. Networking.

5:30 pm Welcome remarks. Alnylam and HSBC.

5:35 pm. Luke’s welcome.

5:40-6:20 pm. Toasts / Roasts / Predictions. How Will the Biopharma World Be Different in 2035?

Speakers:

• Vicki Sato, board chair, Denali Therapeutics, VIR Biotechnology
• John Maraganore, founding CEO, Alnylam Pharmaceuticals
• David Schenkein, general partner, GV
• Andy Plump, president of R&D, Takeda Pharmaceuticals
• Katrine Bosley, founding CEO, DaCapo BrainScience
• Jeremy Levin, CEO, Ovid Therapeutics
• Roger Longman, chairman, Real Endpoints
• Abe Ceesay, CEO, Rapport Therapeutics
• Reid Huber, partner, Third Rock Ventures
• Alex Harding, entrepreneur-in-residence, Atlas Venture; TR correspondent
• Jeb Keiper, CEO, Nimbus Therapeutics
• Katherine Andersen, head of life science and healthcare, HSBC USA Commercial Banking
• David Shaywitz, biopharma R&D executive; TR healthtech columnist
• Bruce Booth, partner, Atlas Venture
• Rosana Kapeller, CEO, Rome Therapeutics

6:20 pm. Networking

7:30 pm. END

 

TR10 West Coast Celebration

Mar. 13, 2025, Adaptive Biotechnologies. 1165 Eastlake Ave. East, Seattle.

5 pm. Registration. Networking.

5:30 pm Welcome from Adaptive.

5:35 pm. Luke’s welcome.

5:40-6:20 pm. Toasts / Roasts / Predictions. How Will the Biopharma World Be Different in 2035?

Speakers:

• Chad Robins, co-founder and CEO, Adaptive Biotechnologies
• Thong Le, senior managing director, Accelerator Life Science Partners
• Bob More, managing director, Alta Partners
• Jim Olson, professor, Seattle Children’s Research Institute; director, Invent@Seattle Children’s Postdoctoral Scholars Program.
• Kelly O’Brien, chief philanthropy officer, Fred Hutch Cancer Center
• Sam Blackman, founder and head of R&D, Day One Biopharmaceuticals
• Brad Loncar, founder, BiotechTV
• Andrew Farnum, co-founder and CEO, Variant Bio
• Aaron Ring, associate professor, translational science and therapeutics division, Fred Hutch Cancer Center; Anderson Family Endowed Chair for Immunotherapy; co-founder, Simcha Therapeutics, ALX Oncology, Seranova Bio, Ab Initio Therapeutics, Stipple Bio
• Andrew Dervan, co-founder and co-CEO, Cajal Neuroscience
• Cliff Stocks, CEO, OncoResponse
• Andy Scharenberg, co-founder and CEO, Umoja Biopharma
• Tae Han, co-founder and former chief strategy officer, ProfoundBio
• Lesley Stolz, vice president, early innovation partnering, Johnson & Johnson Innovation
• Bill Newell, CEO, Sutro Biopharma
• David Younger, co-founder and CEO, A-Alpha Bio

6:20 pm. Networking

7:30 pm. END

All active TR subscribers are welcome to attend. Non-subscribers can purchase an annual subscription — for an individual or a group — at the door.

This will be fun. There may be some teasing. Some wisecracks. I can take it.

Are you a long-term subscriber interested in offering a toast or roast? Perhaps you’d like to sponsor this fun biotech community event? See me luke@timmermanreport.com.

Thank you for your support of this experiment in independent biotech journalism.

Luke